.Pharmacolibrary.Drugs.ATC.R.R07AX31_1 .Pharmacolibrary.Drugs.ATC.R.R07AX31_1| name: | IvacaftorAndTezacaftor_1 | |
| ATC code: | R07AX31_1 | route: | oral |
| compartments: | 2 | |
| dosage: | 100 | mg |
| volume of distribution: | 271 | L |
| clearance: | 14.8 | L/h |
| other parameters in model implementation | ||
Ivacaftor and tezacaftor are combined as a fixed-dose oral therapy indicated for the treatment of cystic fibrosis in patients with specific CFTR gene mutations. Ivacaftor is a CFTR potentiator, increasing chloride transport, while tezacaftor is a CFTR corrector that improves processing and trafficking of the protein to the cell surface. The combination is approved for use in several countries, including the US and EU.
Population pharmacokinetic analysis in healthy adult volunteers; oral administration as fixed combination. Typical population: adults aged 18-50 years, both sexes.